153 related articles for article (PubMed ID: 30802475)
1. Hepatitis E vaccine candidate harboring a non-particulate immunogen of E2 fused with CRM197 fragment A.
Wang K; Zhou L; Zhang X; Song C; Chen T; Li J; Zheng M; Wang Y; Zheng Q; Zheng Z; Yu H; Wu T; Gu Y; Zhang J; Zhao Q; Li S; Xia N
Antiviral Res; 2019 Apr; 164():154-161. PubMed ID: 30802475
[TBL] [Abstract][Full Text] [Related]
2. Real-time stability of a hepatitis E vaccine (Hecolin®) demonstrated with potency assays and multifaceted physicochemical methods.
Zhang X; Wei M; Sun G; Wang X; Li M; Lin Z; Li Z; Li Y; Fang M; Zhang J; Li S; Xia N; Zhao Q
Vaccine; 2016 Nov; 34(48):5871-5877. PubMed ID: 27793484
[TBL] [Abstract][Full Text] [Related]
3. Multimodal investigation of rat hepatitis E virus antigenicity: Implications for infection, diagnostics, and vaccine efficacy.
Sridhar S; Situ J; Cai JP; Yip CC; Wu S; Zhang AJ; Wen L; Chew NF; Chan WM; Poon RW; Chan JF; Tsang DN; Chen H; Xia NS; Yuen KY
J Hepatol; 2021 Jun; 74(6):1315-1324. PubMed ID: 33845058
[TBL] [Abstract][Full Text] [Related]
4. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates.
Li SW; Zhang J; Li YM; Ou SH; Huang GY; He ZQ; Ge SX; Xian YL; Pang SQ; Ng MH; Xia NS
Vaccine; 2005 Apr; 23(22):2893-901. PubMed ID: 15780738
[TBL] [Abstract][Full Text] [Related]
5. Specific memory B cell response and participation of CD4
Kulkarni SP; Thanapati S; Arankalle VA; Tripathy AS
Vaccine; 2016 Nov; 34(48):5895-5902. PubMed ID: 27997340
[TBL] [Abstract][Full Text] [Related]
6. Fusion of C3d molecule with neutralization epitope(s) of hepatitis E virus enhances antibody avidity maturation and neutralizing activity following DNA immunization.
Yang S; Wang C; Fang X; Zhai L; Dong C; Ding L; Meng J; Wang L
Virus Res; 2010 Aug; 151(2):162-9. PubMed ID: 20451569
[TBL] [Abstract][Full Text] [Related]
7. Demonstration of real-time and accelerated stability of hepatitis E vaccine with a combination of different physicochemical and immunochemical methods.
Yin X; Wang X; Zhang Z; Li Y; Lin Z; Pan H; Gu Y; Li S; Zhang J; Xia N; Zhao Q
J Pharm Biomed Anal; 2020 Jan; 177():112880. PubMed ID: 31546137
[TBL] [Abstract][Full Text] [Related]
8. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
[TBL] [Abstract][Full Text] [Related]
9. Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes.
Wei M; Zhang X; Yu H; Tang ZM; Wang K; Li Z; Zheng Z; Li S; Zhang J; Xia N; Zhao Q
Vaccine; 2014 May; 32(24):2859-65. PubMed ID: 24662711
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years.
Yu XY; Chen ZP; Wang SY; Pan HR; Wang ZF; Zhang QF; Shen LZ; Zheng XP; Yan CF; Lu M; Chen B; Zheng Y; Zhang J; Lv HK; Huang SJ
Vaccine; 2019 Jul; 37(32):4581-4586. PubMed ID: 31262585
[TBL] [Abstract][Full Text] [Related]
11. Lessons from hepatitis E vaccine design.
Li S; Zhang J; Xia N
Curr Opin Virol; 2015 Apr; 11():130-6. PubMed ID: 25913817
[TBL] [Abstract][Full Text] [Related]
12. Design and immunogenicity analysis of the combined vaccine against zoonotic hepatitis E and foot-and-mouth disease.
Liu Z; Behloul N; Baha S; Wei W; Shi R; Meng J
Vaccine; 2019 Oct; 37(46):6922-6930. PubMed ID: 31604580
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a fully liquid aluminum phosphate adjuvanted Haemophilus influenzae type b PRP-CRM197-conjugate vaccine in healthy Japanese children: A phase III, randomized, observer-blind, multicenter, parallel-group study.
Togashi T; Mitsuya N; Kogawara O; Sumino S; Takanami Y; Sugizaki K
Vaccine; 2016 Aug; 34(38):4635-4641. PubMed ID: 27265451
[TBL] [Abstract][Full Text] [Related]
14. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity difference between two hepatitis E vaccines derived from genotype 1 and 4.
Wen J; Behloul N; Dai X; Dong C; Liang J; Zhang M; Shi C; Meng J
Antiviral Res; 2016 Apr; 128():36-42. PubMed ID: 26850829
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and protective efficacy in rhesus monkeys of a recombinant ORF2 protein from hepatitis E virus genotype 4.
Huang WJ; Zhang HY; Harrison TJ; Lan HY; Huang GY; Wang YC
Arch Virol; 2009; 154(3):481-8. PubMed ID: 19240977
[TBL] [Abstract][Full Text] [Related]
17. Development of new hepatitis E vaccines.
Cao Y; Bing Z; Guan S; Zhang Z; Wang X
Hum Vaccin Immunother; 2018; 14(9):2254-2262. PubMed ID: 29708836
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and efficacy of a bacterially expressed HEV ORF3 peptide, assessed by experimental infection of primates.
Ma H; Song X; Harrison TJ; Li R; Huang G; Zhang H; Kong W; Wang Y
Arch Virol; 2009; 154(10):1641-8. PubMed ID: 19763777
[TBL] [Abstract][Full Text] [Related]
19. Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope.
Pierce BG; Boucher EN; Piepenbrink KH; Ejemel M; Rapp CA; Thomas WD; Sundberg EJ; Weng Z; Wang Y
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794021
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.
Caro-Aguilar I; Ottinger E; Hepler RW; Nahas DD; Wu C; Good MF; Batzloff M; Joyce JG; Heinrichs JH; Skinner JM
Hum Vaccin Immunother; 2013 Mar; 9(3):488-96. PubMed ID: 23249976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
